Deloitte report showed pharma returns rising to 7%. GLP-1s did most of the work.

Summary

Deloitte's 16th annual pharmaceutical innovation report shows the biopharma sector returning to stronger growth with projected internal rate of return on late-stage pipeline assets rising for the third year, driven primarily by GLP-1 drugs.